Original Article | Published:

Acute lymphoblastic leukemia

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG

Leukemia volume 32, pages 626632 (2018) | Download Citation

Abstract

High-dose methotrexate (Hd-MTX) therapy has recently been applied to the treatment of adult acute lymphoblastic leukemia (ALL) based on pediatric protocols; however, its effectiveness for adult ALL has not yet been confirmed in a rigorous manner. We herein conducted a randomized phase III trial comparing Hd-MTX therapy with intermediate-dose (Id)-MTX therapy. This study was registered at UMIN-CTR (ID: C000000063). Philadelphia chromosome (Ph)-negative ALL patients aged between 25 and 64 years of age were enrolled. Patients who achieved complete remission (CR) were randomly assigned to receive therapy containing Hd-MTX (3 g/m2) or Id-MTX (0.5 g/m2). A total of 360 patients were enrolled. The CR rate was 86%. A total of 115 and 114 patients were assigned to the Hd-MTX and Id-MTX groups, respectively. The estimated 5-year disease-free survival rate of the Hd-MTX group was 58%, which was significantly better than that of the Id-MTX group at 32% (P=0.0218). The frequencies of severe adverse events were not significantly different. We herein demonstrated the effectiveness and safety of Hd-MTX therapy for adult Ph-negative ALL. Our results provide a strong rationale for protocols containing Hd-MTX therapy being applied to the treatment of adult ALL.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95: 3310–3322.

  2. 2.

    , , , , , et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111: 2548–2555.

  3. 3.

    , , , , , et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075–4086.

  4. 4.

    , , , , , et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002; 16: 1259–1266.

  5. 5.

    , , , , , et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561.

  6. 6.

    , , , , , et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106: 3760–3767.

  7. 7.

    , , , , , et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871.

  8. 8.

    , , , , , et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307–1325, ix.

  9. 9.

    , , , , , et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27: 911–918.

  10. 10.

    , , , , , et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008; 26: 1843–1849.

  11. 11.

    , , , , , et al. Augmented Berlin-Frankfurt-Munster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 2014; 120: 3660–3668.

  12. 12.

    , , , , , et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol 2009; 146: 76–85.

  13. 13.

    , , , , , et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J 2014; 4: e252.

  14. 14.

    , , , , , et al. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia 2011; 25: 1697–1703.

  15. 15.

    , , , , , et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646–1654.

  16. 16.

    , . High-dose methotrexate in childhood all. Pediatric Hematol Oncol 2000; 17: 615–622.

  17. 17.

    . Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report. Cancer Res 1967; 27: 2561–2564.

  18. 18.

    , , , , , . Efficacy of high-dose methotrexate in childhood acute lymphocytic leukemia: analysis by contemporary risk classifications. Blood 1988; 71: 866–869.

  19. 19.

    , , , , , et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood 1991; 78: 2514–2519.

  20. 20.

    , , , , , et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314: 471–477.

  21. 21.

    , , , , , et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011; 118: 874–883.

  22. 22.

    , , , , , et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. J Clin Oncol 2016; 34: 2380–2388.

  23. 23.

    , , , , , et al. Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. J Pediatric Hematol Oncol 2014; 36: 353–361.

  24. 24.

    , , , , , et al. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood 2008; 111: 2573–2580.

  25. 25.

    , , , , , et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004; 104: 3507–3512.

  26. 26.

    , , , , , et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458.

  27. 27.

    , , , , , et al. Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. Int J Hematol 2010; 92: 490–502.

  28. 28.

    , , , , , et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460–466.

  29. 29.

    , , , , . Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 2008; 111: 2563–2572.

  30. 30.

    , , , , , et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol 2009; 27: 5189–5194.

  31. 31.

    , , , , , et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. Intergroup Trial C10403. ASH Annu Meet Abstr 2014; 124: 796.

  32. 32.

    , , , , , et al. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol 2016; 172: 439–451.

Download references

Acknowledgements

We thank Masayuki Towatari MD, PhD, Itsuro Jinnai MD, PhD, Daisuke Imanishi MD, PhD and all physicians and staff at the participating centers. We also thank Manami Kira, Midori Fukushima, Saki Amano and Yuko Makino for their secretarial assistance. This work was supported in part by MHLW KAKENHI, MEXT KAKENHI for Programs for Development of Innovative Research on Cancer Therapeutics (P-DIRECT), AMED KAKENHI for Practical Research for Innovative Cancer Control, the National Cancer Center Research and Development Fund (23-A-23) and a grant from the Nonprofit Organization for Support Japan Adult Leukemia Study Group (NPO-JALSG).

Author information

Affiliations

  1. Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan

    • T Sakura
  2. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    • F Hayakawa
    •  & H Kiyoi
  3. Division of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan

    • I Sugiura
  4. Department of Hematology, Hyogo Cancer Center, Akashi, Japan

    • T Murayama
  5. Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan

    • K Imai
  6. Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, Tokyo, Japan

    • N Usui
  7. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

    • S Fujisawa
  8. Faculty of Medical Sciences, Department of Hematology and Oncology, University of Fukui, Yoshida, Japan

    • T Yamauchi
  9. Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan

    • T Yujiri
  10. Hematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan

    • K Kakihana
  11. Department of Hematology, Tokyo Medical University, Tokyo, Japan

    • Y Ito
  12. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    • H Kanamori
  13. Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan

    • Y Ueda
  14. Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    • Y Miyata
  15. Department of Hematology and Oncology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan

    • M Kurokawa
  16. Department of Hematology, Saitama Medical University International Medical Center, Hidaka, Japan

    • N Asou
  17. Japanese Red Cross Aichi Blood Center, Seto, Japan

    • K Ohnishi
  18. Department of Clinical Laboratory Science, Kanazawa University, Kanazawa, Japan

    • S Ohtake
  19. Department of Hematology and Oncology, National Cancer Center Hospital, National Cancer Center, Tokyo, Japan

    • Y Kobayashi
  20. Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan

    • K Matsuo
  21. Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

    • Y Miyazaki
  22. National Hospital Organization Nagoya Medical Center, Nagoya, Japan

    • T Naoe

Authors

  1. Search for T Sakura in:

  2. Search for F Hayakawa in:

  3. Search for I Sugiura in:

  4. Search for T Murayama in:

  5. Search for K Imai in:

  6. Search for N Usui in:

  7. Search for S Fujisawa in:

  8. Search for T Yamauchi in:

  9. Search for T Yujiri in:

  10. Search for K Kakihana in:

  11. Search for Y Ito in:

  12. Search for H Kanamori in:

  13. Search for Y Ueda in:

  14. Search for Y Miyata in:

  15. Search for M Kurokawa in:

  16. Search for N Asou in:

  17. Search for K Ohnishi in:

  18. Search for S Ohtake in:

  19. Search for Y Kobayashi in:

  20. Search for K Matsuo in:

  21. Search for H Kiyoi in:

  22. Search for Y Miyazaki in:

  23. Search for T Naoe in:

Competing interests

Employment: TS (Astellas Pharma) and MK (Celgene, Shionogi, Daiichi Sankyo Foundation of Life Science). Consultancy: TS (Astellas Pharma), NU (CIMIC, Takeda Bio Development Center, Lilly Japan, Pfizer, Nippon Boehiringer-Ingleheim, Sysmex, Janssen, Zenyaku Kogyo, Kyowa hakko Kirin, Astellas Pharma, Otsuka Pharmaceutical, Celgene, SymBio Phrmaceuticals, Huya Bioscience International), YK (Boehiringer-Ingleheim, Novartis), H Kiyoi (Daiichi Sankyo, Celgene, Astellas Pharma, Quintiles), Y Miyazaki (Otsuka, Shire) and TN (Astellas Pharma, Otsuka Pharmaceutical Factory, Fujifilm, Nippon Boehiringer-Ingleheim, Celgene, Dainippon Sumitomo Pharma, Kyowa Hakko Kirin, Pfizer, Toyama Chemical). Stock Ownership: none. Honoraria: FH (Nippon Shinyaku, Dainippon Sumitomo Pharma, Asahi Kasei, Kyowa hakko Kirin, Meiji Seika Pharma), TM (Kyowa Hakko Kirin, Nippon Shinyaku, Taiho Pharmaceutical, Janssen, Siemens, Novartis, Celgene, Ono Pharmaceutical, Pfizer, Bristol-Myers Squibb, Eisai), NU (Chugai Pharmaceutical, Bristol-Myers Squibb, Pfizer, Kyowa Hakko Kirin), SF (Bristol-Myers Squibb, Chugai Pharmaceutical, Celgene, Takeda Pharmaceuticals, Ono Phamaceutical, Pfizer, Alexion Phamaceutical, Shire plc, SHIONOGI CO., LTD, Otsuka Phamaceutical, Sumitomo Dainippon Pharma, Nippon Shinyaku, Astellas Pharma, Novartis, Janssen Pharmaceutical, Eisai, Beckman Coulter), KK (Chugai Pharma, Bristol-Myers Squibb, Kyowa Hakko Kirin, Dainippon Sumitomo Pharma, Celgene), YI (Kyowa Hakko Kirin), H Kanamori (Novartis, Chugai Pharma, Kyowa Hakko Kirin), MK (Kagakuhyoronsha, Nankodo, MSD, Kyowa Hakko Kirin, Ketsuekijohohiroba Tsubasa, Nippon Shinyaku, Yakult, Pfizer, Hokuryukan, Shire, Daiichi Sankyo, New Science, Ono Pharmaceutical, Dainippon Sumitomo Pharma, Celgene, Bristol-Myers Squibb, Takeda), H Kiyoi (Kyowa Hakko Kirin, Pfizer, Shire, Ono Pharmaceutical, Dainippon Sumitomo Pharma, Celgene, Bristol-Myers Squibb, Takeda, Astellas Pharma, Mochida Pharmaceutical, Chugai Pharma, Fujifilm, Alexion Pharmaceuticals, Nippon Kayaku, Sysmex, Amgen Astellas Biopharma, Novartis, Otsuka), Y Miyazaki (Kyowa Hakko Kirin, Celgene, Nippon Shinyaku, Chugai Pharma, Astellas Pharma) and TN (Nippon Boehiringer-Ingleheim, Chugai Pharma, Dainippon Sumitomo Pharma, Kyowa Hakko Kirin, Sysmex, Amgen Astellas Biopharma, Alexion Pharmaceuticals, Daiichi Sankyo, Agios, Eisai). Research Funding: TS (Otsuka Pharmaceutical Factory), NU (Bristol-Myers Squibb, Novartis, Nippon Shinyaku, Fujimoto Pharmaceutical, Celgene, Pfizer), SF (Otsuka Pharmaceutical, Kyowa Hakko Kirin, Ono Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, Pfizer, SHIONOGI CO., LTD, Nippon Shinyaku, Astellas Pharma, MSD), MK (Teijin Pharma, Pfizer, MSD, Toyama Chemical, Astellas Pharma, Kyowa Hakko Kirin, Chugai Pharma), NA (Toyama Chemical, Chugai Pharma), YK (Otsuka Pharmaceutical, Pfizer, Takeda, Astellas Pharma, Daiichi Sankyo) and H Kiyoi (Kyowa Hakko Kirin, Pfizer, Dainippon Sumitomo Pharma, Takeda, Astellas Pharma, Mochida Pharmaceutical, Chugai Pharma, Fujifilm, Alexion Pharmaceuticals, Novartis, Nippon Boehiringer-Ingleheim, Toyama Chemical, Zenyaku Kogyo, Nippon Shinyaku, Yakult, Eisai, MSD, JCR Pharma, Meiji Seika Pharma).Expert Testimony: none. Other potential financial relationships: none.

Corresponding author

Correspondence to F Hayakawa.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/leu.2017.283

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)